Bioceres Crop Solutions (NASDAQ:BIOX) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of Bioceres Crop Solutions (NASDAQ:BIOX - Free Report) from a hold rating to a sell rating in a research report report published on Friday.

Separately, Oppenheimer cut their target price on shares of Bioceres Crop Solutions from $7.00 to $6.00 and set an "outperform" rating for the company in a research note on Tuesday, July 15th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.38.

Bioceres Crop Solutions Trading Up 2.9%

NASDAQ BIOX traded up $0.11 during trading hours on Friday, hitting $3.67. The company's stock had a trading volume of 62,899 shares, compared to its average volume of 184,232. The stock has a fifty day moving average of $4.59 and a 200 day moving average of $4.92. Bioceres Crop Solutions has a twelve month low of $3.51 and a twelve month high of $11.41. The firm has a market capitalization of $229.83 million, a P/E ratio of -26.22, a PEG ratio of 1.54 and a beta of 0.41. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.22.

Bioceres Crop Solutions (NASDAQ:BIOX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 21st. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.08. The company had revenue of $59.60 million during the quarter, compared to the consensus estimate of $61.80 million. Bioceres Crop Solutions had a negative net margin of 2.14% and a negative return on equity of 2.37%. Equities research analysts forecast that Bioceres Crop Solutions will post -0.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bioceres Crop Solutions

Several hedge funds and other institutional investors have recently made changes to their positions in BIOX. JPMorgan Chase & Co. grew its holdings in shares of Bioceres Crop Solutions by 17.0% during the 4th quarter. JPMorgan Chase & Co. now owns 105,301 shares of the company's stock valued at $640,000 after purchasing an additional 15,328 shares during the last quarter. Ballast Asset Management LP boosted its stake in shares of Bioceres Crop Solutions by 23.5% in the 4th quarter. Ballast Asset Management LP now owns 431,887 shares of the company's stock valued at $2,620,000 after purchasing an additional 82,187 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Bioceres Crop Solutions in the 4th quarter valued at $72,000. Stifel Financial Corp boosted its stake in shares of Bioceres Crop Solutions by 51.9% in the 4th quarter. Stifel Financial Corp now owns 61,958 shares of the company's stock valued at $377,000 after purchasing an additional 21,168 shares during the last quarter. Finally, Long Focus Capital Management LLC lifted its position in shares of Bioceres Crop Solutions by 130.7% during the 4th quarter. Long Focus Capital Management LLC now owns 744,748 shares of the company's stock valued at $4,528,000 after acquiring an additional 421,931 shares during the period. 17.68% of the stock is currently owned by institutional investors and hedge funds.

Bioceres Crop Solutions Company Profile

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.